WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140015) SITE-DIRECTED MODIFICATION OF FACTOR IX
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140015    International Application No.:    PCT/US2009/040691
Publication Date: 19.11.2009 International Filing Date: 15.04.2009
IPC:
A61K 38/48 (2006.01)
Applicants: BAYER HEALTHCARE LLC [US/US]; 555 White Plains Road Tarrytown, NY 10591 (US) (For All Designated States Except US).
BROOKS, Alan, R. [GB/US]; (US) (For US Only).
MURPHY, John, E. [US/US]; (US) (For US Only).
SETO, Marian [US/US]; (US) (For US Only).
JIANG, Xiaoqiao [US/US]; (US) (For US Only).
KIEWLICH, David [US/US]; (US) (For US Only).
PATEL, Chandra [US/US]; (US) (For US Only)
Inventors: BROOKS, Alan, R.; (US).
MURPHY, John, E.; (US).
SETO, Marian; (US).
JIANG, Xiaoqiao; (US).
KIEWLICH, David; (US).
PATEL, Chandra; (US)
Agent: PELLEGRINO, Susan, M.; (US)
Priority Data:
61/124,568 16.04.2008 US
Title (EN) SITE-DIRECTED MODIFICATION OF FACTOR IX
(FR) MODIFICATION DE FACTEUR IX ORIENTÉE SITE
Abstract: front page image
(EN)The invention relates to modified Factor IX polypeptides such as Factor IX polypeptides with one or more introduced cysteine sites. The modified Factor IX polypeptides may be conjugated to a biocompatible polymer. The invention also relates to methods of making modified Factor IX polypeptides, and methods of using modified Factor IX polypeptides, for example, to treat patients afflicted with hemophilia B.
(FR)L'invention concerne des polypeptides du facteur IX modifié, tels que des polypeptides du facteur IX dans lesquels un ou plusieurs sites cystéine ont été introduits. Les polypeptides du facteur IX modifié peuvent être conjugués avec un polymère biocompatible. L'invention concerne également des procédés pour produire des polypeptides du facteur IX modifié, et des méthodes pour utiliser lesdits polypeptides du facteur IX modifié, par exemple, pour traiter des patients souffrant d'hémophilie B.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)